2 results
Not approvedWill not start
The primary objective is to study whether treatment with the mTOR inhibitor Everolimus results in an objectable change in phosphorylation of the selected downstream effectors 4eBP1 and p70S6K in human prostate cancer biopsies. A secondary objective…
Approved WMOCompleted
Primary objective: To evaluate the safety and tolerability of GSK1795091 when administered in combination with either GSK3174998, GSK3359609, orpembrolizumab.Secondary objectives: * To evaluate the antitumor activity of GSK1795091 when administered…